OncoMatch/Clinical Trials/NCT06522919
Sequential Immunochemotherapy Treatment with Pembrolizumab Plus Dendritic Cell (DC) Vaccine Followed by Trifluridine/Tipiracil Plus Bevacizumab in Refractory Mismatch-repair-proficient (pMMR) or Microsatellite-stable (MSS) Metastatic Colorectal Cancer
Is NCT06522919 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Autologous Dendritic Cell (DC) Vaccine for colorectal cancer metastatic.
Treatment: Autologous Dendritic Cell (DC) Vaccine — Single-arm, open-label, multicenter phase 2 clinical trial evaluating the clinical and the immunological activity of an innovative strategy with an induction combo immunotherapy (Pembrolizumab plus DC Vaccine) followed by a maintenance chemotherapy (FTD/TPI plus Bevacizumab) in patients with refractory MSS/pMMR metastatic colorectal cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Colorectal Cancer
Biomarker criteria
Required: MSI1 microsatellite stable
Histologically confirmed pMMR or MSS mCRC
Required: Mismatch-repair proficient (pMMR / MSS)
Histologically confirmed pMMR or MSS mCRC
Allowed: KRAS wild-type
anti-EGFR monoclonal antibody for RAS wild-type tumors
Allowed: NRAS wild-type
anti-EGFR monoclonal antibody for RAS wild-type tumors
Disease stage
Required: Stage IV
Metastatic disease required
Patients must have measurable disease by RECIST v 1.1 criteria on CT (or MRI) scan of the chest, abdomen and pelvis.
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: chemotherapy (fluoropyrimidines, irinotecan, oxaliplatin) — advanced
Prior treatment with 1-2 chemotherapy regimens in an advanced setting, including (if not contraindicated) fluoropyrimidines, irinotecan, oxaliplatin
Must have received: anti-VEGF monoclonal antibody — advanced
including...an anti-VEGF monoclonal antibody
Must have received: anti-EGFR monoclonal antibody — advanced
including...anti-EGFR monoclonal antibody for RAS wild-type tumors
Cannot have received: trifluridine/tipiracil (FTD/TPI)
Prior treatment with FTD/TPI for mCRC
Lab requirements
Blood counts
leukocytes >3,000/μl, absolute neutrophil count >1,500/μl, platelets >100,000/μl
Kidney function
creatinine < 1.5 x uln or creatinine clearance >30 ml/min/1.73 m2
Liver function
total bilirubin < 1.5 x institutional upper limit of normal (uln), ast(sgot)/alt(sgpt) <2.5 x uln
Cardiac function
normal cardiological parameters (12-lead ecg and echocardiogram)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06522919 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior trifluridine/tipiracil disqualifies patients from enrollment.
Does this trial require MSH2?
Yes, MSH2 proficient mismatch repair is a required biomarker for enrollment.
Does this trial require MSH6?
Yes, MSH6 proficient mismatch repair is a required biomarker for enrollment.
Does this trial require MLH1?
Yes, MLH1 proficient mismatch repair is a required biomarker for enrollment.
What disease stage is eligible?
Stage IV is required (metastatic disease required).
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages